Geode Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $82.7M | Buy |
1,370,114
+277,182
| +25% | +$15.4M | ﹤0.01% | 1326 |
|
|
2026
Q1 | $63.5M | Buy |
1,092,932
+140,253
| +15% | +$6.46M | ﹤0.01% | 1359 |
|
|
2025
Q4 | $42.7M | Sell |
952,679
-24,756
| -3% | -$1.04M | ﹤0.01% | 1588 |
|
|
2025
Q3 | $39.2M | Buy |
977,435
+7,092
| +0.7% | +$250K | ﹤0.01% | 1633 |
|
|
2025
Q2 | $30.4M | Buy |
970,343
+900,746
| +1,294% | +$29.4M | ﹤0.01% | 1725 |
|
|
2025
Q1 | $2.33M | Buy |
69,597
+68
| +0.1% | +$2.58K | ﹤0.01% | 2979 |
|
|
2024
Q4 | $2.73M | Buy |
69,529
+720
| +1% | +$29.8K | ﹤0.01% | 3025 |
|
|
2024
Q3 | $2.71M | Sell |
68,809
-120
| -0.2% | -$4.84K | ﹤0.01% | 3029 |
|
|
2024
Q2 | $2.69M | Buy |
68,929
+4,700
| +7% | +$188K | ﹤0.01% | 3030 |
|
|
2024
Q1 | $2.77M | Buy |
64,229
+2,156
| +3% | +$99.2K | ﹤0.01% | 2986 |
|
|
2023
Q4 | $2.86M | Buy |
62,073
+6,128
| +11% | +$217K | ﹤0.01% | 2977 |
|
|
2023
Q3 | $1.91M | Buy |
55,945
+30
| +0.1% | +$1.12K | ﹤0.01% | 3091 |
|
|
2023
Q2 | $2.15M | Buy |
55,915
+190
| +0.3% | +$7.55K | ﹤0.01% | 3088 |
|
|
2023
Q1 | $1.99M | Buy |
55,725
+440
| +0.8% | +$16.3K | ﹤0.01% | 3030 |
|
|
2022
Q4 | $2.18M | Sell |
55,285
-6,538
| -11% | -$238K | ﹤0.01% | 3002 |
|
|
2022
Q3 | $2.23M | Buy |
61,823
+16,307
| +36% | +$586K | ﹤0.01% | 3044 |
|
|
2022
Q2 | $1.38M | Buy |
45,516
+17,318
| +61% | +$524K | ﹤0.01% | 3269 |
|
|
2022
Q1 | $862K | Hold |
28,198
| – | – | ﹤0.01% | 3681 |
|
|
2021
Q4 | $880K | Buy |
28,198
+6,548
| +30% | +$196K | ﹤0.01% | 3772 |
|
|
2021
Q3 | $330K | Hold |
21,650
| – | – | ﹤0.01% | 4220 |
|
|
2021
Q2 | $403K | Buy |
21,650
+2,408
| +13% | +$44.4K | ﹤0.01% | 4037 |
|
|
2021
Q1 | $344K | Hold |
19,242
| – | – | ﹤0.01% | 3939 |
|
|
2020
Q4 | $295K | Hold |
19,242
| – | – | ﹤0.01% | 3762 |
|
|
2020
Q3 | $213K | Hold |
19,242
| – | – | ﹤0.01% | 3699 |
|
|
2020
Q2 | $241K | Hold |
19,242
| – | – | ﹤0.01% | 3610 |
|
|
2020
Q1 | $218K | Hold |
19,242
| – | – | ﹤0.01% | 3525 |
|
|
2019
Q4 | $252K | Hold |
19,242
| – | – | ﹤0.01% | 3722 |
|
|
2019
Q3 | $173K | Hold |
19,242
| – | – | ﹤0.01% | 3822 |
|
|
2019
Q2 | $189K | Buy |
19,242
+5,158
| +37% | +$49.4K | ﹤0.01% | 3804 |
|
|
2019
Q1 | $143K | Hold |
14,084
| – | – | ﹤0.01% | 3819 |
|
|
2018
Q4 | $88K | Buy |
+14,084
| New | +$125K | ﹤0.01% | 3886 |
|
|
2017
Q2 | – | Sell |
-10,386
| Closed | -$41K | – | 4112 |
|
|
2017
Q1 | $41K | Buy |
10,386
+366
| +4% | +$2.88K | ﹤0.01% | 3977 |
|
|
2016
Q4 | $77K | Buy |
+10,020
| New | +$80.5K | ﹤0.01% | 3836 |
|
Other funds holding XENE
ACA
PCH
DCM
JT
Geode Capital Management's XENE Position: Q2 2026 in Review
Geode Capital Management increased its Xenon Pharmaceuticals (XENE) stake by 25% in Q2 2026, buying an estimated $15.4M and bringing the position to 1,370,114 shares worth $82.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1326.
Geode Capital Management first reported a position in XENE in Q4 2016 and has held it in 33 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.
- Geode Capital Management held 1,370,114 shares of Xenon Pharmaceuticals worth $82.7M as of Q2 2026.
- Geode Capital Management bought 277,182 Xenon Pharmaceuticals shares in Q2 2026, an estimated $15.4M.
- Xenon Pharmaceuticals made up ﹤0.01% of Geode Capital Management's portfolio in Q2 2026, its #1326 holding.
- Geode Capital Management first reported a position in Xenon Pharmaceuticals in Q4 2016 and has held it in 33 quarters since.
- 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.
Based on Geode Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.